Zobrazeno 1 - 10
of 926
pro vyhledávání: '"5-asa"'
Autor:
Shilpa Sahu, Prasanta Kumar Choudhury, Gourishyam Pasa, Padala Narasimha Murthy, Poonam Sahu, Renuka Verma
Publikováno v:
Journal of Applied Pharmaceutical Research, Vol 12, Iss 2, Pp 93-108 (2024)
Background: Inflammatory bowel diseases (IBD) require effective colon-targeted drug delivery for improved therapeutic efficacy and minimized systemic side effects. Objectives: The objective of this research was to develop and evaluate novel colon-tar
Externí odkaz:
https://doaj.org/article/03241e9281af4768a809723d0bd33dc7
Publikováno v:
Frontiers in Gastroenterology, Vol 3 (2024)
Mesalazine is an established and recommended first-line treatment for mild-to-moderate ulcerative colitis (UC). For patients with moderately active UC, the choice to use mesalazine or to initiate treatment with an oral corticosteroid or anti-tumor ne
Externí odkaz:
https://doaj.org/article/4c8f9a2c11b64d4db6512b01305507f2
Autor:
Hiroshi Matsumoto, Momoyo Sasahira, Tei Tei Go, Shogen Yo, Takehiro Ninomiya, Motoyasu Osawa, Osamu Handa, Eiji Umegami, Ryo Inoue, Akiko Shiotani
Publikováno v:
Biomedicines, Vol 12, Iss 9, p 2125 (2024)
Background/Objectives: 5-Aminosalicylic acid (5-ASA) is a first-line therapy for ulcerative colitis (UC). This study examined the mucosa-associated microbiota (MAM) in UC patients, distinguishing between those who were 5-ASA tolerant and intolerant.
Externí odkaz:
https://doaj.org/article/d44944935a304228bb35af5f9d3d042e
Autor:
Antonio Tursi, Alessandro D’Avino, Giovanni Brandimarte, Giammarco Mocci, Raffaele Pellegrino, Edoardo Vincenzo Savarino, Antonietta Gerarda Gravina, the HERICIUM-UC Study Group
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1133 (2024)
Mild-to-moderate ulcerative colitis (UC) management is centred on 5-aminosalicylic acid (5-ASA) derivatives. Whether supplementing 5-ASA with nutraceuticals can provide real advantages in UC-relevant outcomes is unclear. This retrospective multicentr
Externí odkaz:
https://doaj.org/article/34445076b2024702bad11f74d6048e61
Autor:
Lei Qiu, Renbin Shen, Lei Wei, Shujuan Xu, Wei Xia, Yan Hou, Jinxin Cui, Rong Qu, Jiale Luo, Jian Cao, Jie Yang, Jing Sun, Ronglin Ma, Qiang Yu
Publikováno v:
Journal of Nanobiotechnology, Vol 21, Iss 1, Pp 1-19 (2023)
Abstract Patients with inflammatory bowel disease (IBD) always suffer from severe abdominal pain and appear to be at high risk for colorectal cancer. Recently, the co-delivery of targeted drugs and gut microbiota has developed into an attractive stra
Externí odkaz:
https://doaj.org/article/852af64bff9c449288f766ca48324764
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ohtaki Yuichiro, Uchiyama Kan, Kamiya Hirotaka, Moriizumi Eri, Yamada Moe, Aoki Yuma, Watanabe Toshimune, Kiryu Sachie, Suzuki Sizuka, Matsumoto Yoshihiro, Ito Zensho, Ohkusa Toshifumi, Koido Shigeo, Saruta Masayuki
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background Multi-matrix mesalazine (MMX) is an important treatment for ulcerative colitis (UC); however, it is often excreted intact, which increases the risk of relapse. This study aimed to clarify the risk factors for insoluble MMX excreti
Externí odkaz:
https://doaj.org/article/6ca23db89d6b49e58d4c49e93a3d8761
Autor:
Izabela Lima, Lina Moreno, Sávia Dias, Durcilene Silva, Antônia Carla Oliveira, Lamartine Soares, Rayran Sousa, Dalton Dittz, Hercília Rolim, Lívio Nunes
Publikováno v:
Carbohydrate Polymer Technologies and Applications, Vol 5, Iss , Pp 100265- (2023)
We encapsulated mesalazine (MSZ) in nanoparticles (NP) of acetylated cashew gum (ACG) in order to improve its absorption in the colon. NPs were synthesized by the dialysis method and different polymer:drug ratios (10:1, 10:2 and 10:5) were investigat
Externí odkaz:
https://doaj.org/article/f1cfc8310b31478ca609d29477c68220
Autor:
Ryosuke Miyazaki, Toshiyuki Sakurai, Mariko Shimada, Yuko Iwashita, Naoki Shibuya, Yoshihiro Akita, Haruna Miyashita, Yuki Maruyama, Masayuki Saruta
Publikováno v:
BMC Gastroenterology, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Introduction Patients with ulcerative colitis (UC) are known to have a significantly poor quality of life due to bowel frequency (night) and urgent defecation. Budesonide foam is a topical medication that was approved in Japan in 2017 for th
Externí odkaz:
https://doaj.org/article/db77b0ffadbe4ff191c98d9d45052e72
Publikováno v:
Molecules, Vol 28, Iss 24, p 8105 (2023)
Mesalamine, also called 5-ASA (5-aminosalicylic acid), is a largely used anti-inflammatory agent and is a main choice to treat Ulcerative Colitis. This report is aimed to investigate enzymatic processes involved in the oxidation of mesalamine to bett
Externí odkaz:
https://doaj.org/article/4bda1a6832994b1aa728ab4e4cc1e9ee